We're a very good fit.

Merck is pleased that it has the opportunity to develop what appears to be a very promising treatment for NSCLC, which is one of the most prevalent and deadly of all cancers. We believe this new agreement is not only beneficial for both companies but also for patients.

If we lose, that will lead to a massive drop in sales.

It is not a good message, because it shows the Quartet does not follow the same line.

This lecture took place 17 years ago. He is an English citizen. He doesn't live in Austria and he is 68 years old. He is not really dangerous, especially not to Austria.

There have been problems for decades, but it's been better in the past couple of years. One of the reasons, definitely, is a better presence in the media.